Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-cash Items: 2021-2025

Historic Non-cash Items for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $11.8 million.

  • SAB Biotherapeutics' Non-cash Items rose 71.01% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 71.01%. This contributed to the annual value of $6.3 million for FY2024, which is 847.42% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Non-cash Items of $11.8 million as of Q3 2025, which was up 126.92% from $5.2 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Non-cash Items high stood at $28.9 million for Q4 2021, and its period low was $109,891 during Q4 2022.
  • Its 3-year average for Non-cash Items is $5.5 million, with a median of $5.2 million in 2025.
  • Per our database at Business Quant, SAB Biotherapeutics' Non-cash Items tumbled by 99.62% in 2022 and then soared by 847.42% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Non-cash Items (Quarterly) stood at $28.9 million in 2021, then tumbled by 99.62% to $109,891 in 2022, then spiked by 505.12% to $664,967 in 2023, then surged by 847.42% to $6.3 million in 2024, then skyrocketed by 71.01% to $11.8 million in 2025.
  • Its last three reported values are $11.8 million in Q3 2025, $5.2 million for Q2 2025, and $5.7 million during Q1 2025.